Breakthrough trial shows donanemab slows alzheimer’s progression
Dementia Australia has welcomed the publication of the results of a trial showing that a new drug, donanemab, has been able to slow the progression
Risky but effective: New Alzheimer’s drug donanemab shows promising results
Eli Lilly and Company’s new drug, donanemab, has shown promising results in slowing cognitive decline by 35% in people with early symptoms of Alzheimer’s disease.
